OBJ LIMITED (ASX:OBJ) has been granted a trading halt by the ASX pending a product launch.
The company develops proprietary magnetic micro‐array drug delivery and product enhancement technologies for the pharmaceutical, healthcare and consumer goods sectors.
OBJ also partners with companies in the design and development of products.
In April this year OBJ signed a wide ranging Product Development Agreement with the US$230 billion capped Procter & Gamble (NYSE:PG).
The halt will remain in place until the opening of trade on Wednesday 1st October 2014, or earlier if an announcement is made to the market.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.